PapersPMID:17532963
Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study.
What moved
1 findingHow to read these marks →- Decreases incidence of myocardial infarction
very limited
“Myocardial infarctions with peak creatinine kinase-myocardial band> or =100 ng/mL were reduced by 47.2% in the MC-1 250-mg group versus placebo (P = .0083).”
- Study
- RCT
- Duration
- 4 weeks
- Dose studied
- MC-1 (pyridoxal-5'-phosphate monohydrate) 250 mg once daily from 3 to 10 hours before surgery to postoperative day 30
- Population
- High-risk patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass; MC-1 250 mg arm against placebo, myocardial infarction defined as peak CK-MB at least 100 ng/mL
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- patients scheduled for coronary artery bypass graft surgery with cardiopulmonary bypass at high risk for subsequent cardiac or neurologic complications
- Participants
- 901
- Comparator
- placebo
- Duration
- 30 days
- Endpoints measured
- 5